Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inverness Medical Innovations

This article was originally published in The Tan Sheet

Executive Summary

Pregnancy tests "will be the engine of growth for the company in the next several quarters," Chairman & CEO Ron Zwanziger says during Feb. 20 analysts call. Waltham, Mass.-based firm will introduce a "new-format digital pregnancy test" before the end of 2003, earlier than previously expected. Potential outcomes of pregnancy test patent infringement suit against Pfizer were not factored into Inverness' projections; the firm recently obtained a preliminary injunction against Pfizer's e.p.t. test kits (1"The Tan Sheet" Jan. 6, 2003, In Brief). Inverness expects Q1 2003 net revenues of $63 mil. and annual revenues of $275 mil. Firm saw 2002 net sales leap 339.5% to $207.9 mil., due to its acquisition and integration of the Unipath women's health group, the IVC supplement business and the diagnostic firm Wampole, Inverness says in 2Feb. 20 release. Net income for the year was $1.4 mil., compared to last year's $4 mil. loss...
Advertisement

Related Content

Inverness v. Pfizer

Topics

Advertisement
UsernamePublicRestriction

Register

PS095165

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel